|
|
News Breaks | | | | November 27, 2012 | | 08:48 EDT |  | NKTR, SLXP | Nektar shares undervalued, says Roth Capital
After Nektar's (NKTR) migraine treatment, Levadex, received an April 2013 action date by the FDA, Roth Capital thinks the company's assets are worth much more than the amount reflected by the company's stock. The firm doesn't expect Nektar's Naloxegol in opioid-related constipation to experience the same issues with the FDA as a potential competing product made by Salix (SLXP). Roth maintains a $12 price target and Buy rating on Nektar. | |
|
News For NKTR;SLXP From The Last 14 Days Check below for free stories on NKTR;SLXP the last two weeks. |
|
|
| May 23, 2013 | | 12:35 EDT |  | SLXP | Salix management to meet with Jefferies
 Subscribe for More Information | | | May 22, 2013 | | 07:07 EDT |  | SLXP | Salix announces statistically significant results for budesonide foam
Salix Pharmaceuticals announced the successful completion and outcome of two pivotal Phase 3 studies to evaluate the efficacy and safety of budesonide foam in the treatment of active mild to moderate ulcerative proctitis, UP, or ulcerative proctosigmoiditis, UPS. In each of the two pivotal Phase 3 studies, a statistically significant proportion of subjects treated with budesonide foam achieved clinical remission compared to subjects treated with placebo foam. The company said, “We are pleased with the outcome of our pivotal studies of budesonide foam in the treatment of UP and UPS...We believe foam formulations provide important advantages over enema formulations principally with respect to drug retention and patient acceptance. We are working to submit a New Drug Application for budesonide foam as a treatment for UP and UPS by the end of September 2013. If approved, budesonide foam would be the first foam product approved in the United States for patients with UP...as well as for patients suffering from UPS." | | | May 21, 2013 | | 09:29 EDT | | NKTR | AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpoints
AstraZeneca (AZN) presented the results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previous studies. Data was presented at the Digestive Disease Week meeting in Orlando, Florida. The primary endpoint in both trials was percentage of OIC responders, versus placebo, over 12 weeks of treatment. The secondary endpoints included the 12-week response rate in a laxative inadequate response population, the median time to first spontaneous bowel movement and the number of days per-week with at least one bowel movement. Plans for naloxegol will be finalized over the coming months, incorporating the outcome of ongoing discussions with health authorities in the US, EU and Canada, the company said. Naloxegol, a peripherally-acting mu-opioid receptor antagonist, has been specifically designed for the treatment of opioid-induced constipation and is part of the exclusive worldwide license agreement announced on 21 September 2009, between AstraZeneca and Nektar Therapeutics (NKTR). | | | May 17, 2013 | | 10:36 EDT | | NKTR, SLXP | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
Subscribe for More Information | | | May 10, 2013 | | 10:37 EDT | | NKTR | Nektar shares should be bought on weakness, says MKM Partners
Subscribe for More Information | | | 10:00 EDT |  | SLXP | On The Fly: Analyst Downgrade Summary
Subscribe for More Information | | | 08:07 EDT | | SLXP | Salix price target raised to $57 from $53 at Brean Capital
Subscribe for More Information | | | 06:31 EDT | | SLXP | Salix downgraded to Neutral from Buy at Janney Capital
Subscribe for More Information | |
|
|
|
|
|
|
